This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To evaluate the benefits and harms of biological agents targeting type-2 inflammation (benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, tezepelumab) in people with severe asthma, with a network meta-analysis and to rank agents by effectiveness.